Sinovac Biotech (SVA) Competitors

$6.47 0.00 (0.00%)

As of 05/22/2026

SVA vs. GPCR, IDYA, IRON, ARQT, and VERA

Should you buy Sinovac Biotech stock or one of its competitors? MarketBeat compares Sinovac Biotech with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Sinovac Biotech include Structure Therapeutics (GPCR), IDEAYA Biosciences (IDYA), Disc Medicine (IRON), Arcutis Biotherapeutics (ARQT), and Vera Therapeutics (VERA). These companies are all part of the "med - biomed/gene" industry.

How does Sinovac Biotech compare to Structure Therapeutics?

Sinovac Biotech (NASDAQ:SVA) and Structure Therapeutics (NASDAQ:GPCR) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, earnings, media sentiment, institutional ownership, profitability and dividends.

Sinovac Biotech has higher revenue and earnings than Structure Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sinovac Biotech	$361.37M	1.78	$90.90M	N/A	N/A
Structure Therapeutics	N/A	N/A	-$141.20M	-$0.87	N/A

In the previous week, Structure Therapeutics had 2 more articles in the media than Sinovac Biotech. MarketBeat recorded 2 mentions for Structure Therapeutics and 0 mentions for Sinovac Biotech. Structure Therapeutics' average media sentiment score of 0.68 beat Sinovac Biotech's score of 0.00 indicating that Structure Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Sinovac Biotech	Neutral
Structure Therapeutics	Positive

Structure Therapeutics has a consensus price target of $109.25, suggesting a potential upside of 178.77%. Given Structure Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Structure Therapeutics is more favorable than Sinovac Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sinovac Biotech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	3 Strong Buy rating(s)	2.89

Sinovac Biotech has a beta of 0.79, meaning that its stock price is 21% less volatile than the broader market. Comparatively, Structure Therapeutics has a beta of -1.31, meaning that its stock price is 231% less volatile than the broader market.

91.8% of Structure Therapeutics shares are held by institutional investors. 12.8% of Sinovac Biotech shares are held by company insiders. Comparatively, 5.6% of Structure Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Sinovac Biotech's return on equity of 0.00% beat Structure Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sinovac Biotech	N/A	N/A	N/A
Structure Therapeutics	N/A	-24.91%	-23.67%

Summary

Structure Therapeutics beats Sinovac Biotech on 7 of the 13 factors compared between the two stocks.

How does Sinovac Biotech compare to IDEAYA Biosciences?

Sinovac Biotech (NASDAQ:SVA) and IDEAYA Biosciences (NASDAQ:IDYA) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, risk, dividends and analyst recommendations.

98.3% of IDEAYA Biosciences shares are held by institutional investors. 12.8% of Sinovac Biotech shares are held by insiders. Comparatively, 4.7% of IDEAYA Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Sinovac Biotech's return on equity of 0.00% beat IDEAYA Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sinovac Biotech	N/A	N/A	N/A
IDEAYA Biosciences	N/A	-14.24%	-13.09%

IDEAYA Biosciences has a consensus target price of $50.69, suggesting a potential upside of 74.18%. Given IDEAYA Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe IDEAYA Biosciences is more favorable than Sinovac Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sinovac Biotech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
IDEAYA Biosciences	1 Sell rating(s)	1 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.82

Sinovac Biotech has a beta of 0.79, indicating that its share price is 21% less volatile than the broader market. Comparatively, IDEAYA Biosciences has a beta of -0.04, indicating that its share price is 104% less volatile than the broader market.

Sinovac Biotech has higher revenue and earnings than IDEAYA Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sinovac Biotech	$361.37M	1.78	$90.90M	N/A	N/A
IDEAYA Biosciences	$218.71M	11.69	-$113.70M	-$1.60	N/A

In the previous week, IDEAYA Biosciences had 2 more articles in the media than Sinovac Biotech. MarketBeat recorded 2 mentions for IDEAYA Biosciences and 0 mentions for Sinovac Biotech. Sinovac Biotech's average media sentiment score of 0.00 beat IDEAYA Biosciences' score of -0.17 indicating that Sinovac Biotech is being referred to more favorably in the media.

Company	Overall Sentiment
Sinovac Biotech	Neutral
IDEAYA Biosciences	Neutral

Summary

Sinovac Biotech beats IDEAYA Biosciences on 7 of the 13 factors compared between the two stocks.

How does Sinovac Biotech compare to Disc Medicine?

Disc Medicine (NASDAQ:IRON) and Sinovac Biotech (NASDAQ:SVA) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, media sentiment, dividends, earnings and valuation.

83.7% of Disc Medicine shares are owned by institutional investors. 3.8% of Disc Medicine shares are owned by insiders. Comparatively, 12.8% of Sinovac Biotech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Sinovac Biotech's return on equity of 0.00% beat Disc Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Disc Medicine	N/A	-36.94%	-33.88%
Sinovac Biotech	N/A	N/A	N/A

Sinovac Biotech has higher revenue and earnings than Disc Medicine.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Disc Medicine	N/A	N/A	-$212.18M	-$6.62	N/A
Sinovac Biotech	$361.37M	1.78	$90.90M	N/A	N/A

In the previous week, Disc Medicine had 6 more articles in the media than Sinovac Biotech. MarketBeat recorded 6 mentions for Disc Medicine and 0 mentions for Sinovac Biotech. Disc Medicine's average media sentiment score of 0.60 beat Sinovac Biotech's score of 0.00 indicating that Disc Medicine is being referred to more favorably in the media.

Company	Overall Sentiment
Disc Medicine	Positive
Sinovac Biotech	Neutral

Disc Medicine currently has a consensus price target of $105.30, indicating a potential upside of 57.59%. Given Disc Medicine's stronger consensus rating and higher possible upside, research analysts clearly believe Disc Medicine is more favorable than Sinovac Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Disc Medicine	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Sinovac Biotech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Disc Medicine has a beta of 0.93, meaning that its share price is 7% less volatile than the broader market. Comparatively, Sinovac Biotech has a beta of 0.79, meaning that its share price is 21% less volatile than the broader market.

Summary

Disc Medicine beats Sinovac Biotech on 7 of the 12 factors compared between the two stocks.

How does Sinovac Biotech compare to Arcutis Biotherapeutics?

Arcutis Biotherapeutics (NASDAQ:ARQT) and Sinovac Biotech (NASDAQ:SVA) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, dividends, analyst recommendations, profitability, earnings and valuation.

Arcutis Biotherapeutics presently has a consensus target price of $34.00, indicating a potential upside of 62.99%. Given Arcutis Biotherapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Arcutis Biotherapeutics is more favorable than Sinovac Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcutis Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Sinovac Biotech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Sinovac Biotech has a net margin of 0.00% compared to Arcutis Biotherapeutics' net margin of -0.57%. Sinovac Biotech's return on equity of 0.00% beat Arcutis Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcutis Biotherapeutics	-0.57%	-1.41%	-0.59%
Sinovac Biotech	N/A	N/A	N/A

In the previous week, Arcutis Biotherapeutics' average media sentiment score of 0.00 equaled Sinovac Biotech'saverage media sentiment score.

Company	Overall Sentiment
Arcutis Biotherapeutics	Neutral
Sinovac Biotech	Neutral

Sinovac Biotech has lower revenue, but higher earnings than Arcutis Biotherapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcutis Biotherapeutics	$376.07M	6.94	-$16.14M	-$0.03	N/A
Sinovac Biotech	$361.37M	1.78	$90.90M	N/A	N/A

Arcutis Biotherapeutics has a beta of 1.58, meaning that its share price is 58% more volatile than the broader market. Comparatively, Sinovac Biotech has a beta of 0.79, meaning that its share price is 21% less volatile than the broader market.

Summary

Arcutis Biotherapeutics beats Sinovac Biotech on 6 of the 10 factors compared between the two stocks.

How does Sinovac Biotech compare to Vera Therapeutics?

Sinovac Biotech (NASDAQ:SVA) and Vera Therapeutics (NASDAQ:VERA) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, earnings, valuation, media sentiment, profitability and analyst recommendations.

Sinovac Biotech has a beta of 0.79, indicating that its share price is 21% less volatile than the broader market. Comparatively, Vera Therapeutics has a beta of 0.96, indicating that its share price is 4% less volatile than the broader market.

Vera Therapeutics has a consensus price target of $79.00, suggesting a potential upside of 132.08%. Given Vera Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Vera Therapeutics is more favorable than Sinovac Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sinovac Biotech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Vera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

Sinovac Biotech has higher revenue and earnings than Vera Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sinovac Biotech	$361.37M	1.78	$90.90M	N/A	N/A
Vera Therapeutics	N/A	N/A	-$299.61M	-$5.54	N/A

99.2% of Vera Therapeutics shares are held by institutional investors. 12.8% of Sinovac Biotech shares are held by insiders. Comparatively, 15.9% of Vera Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Sinovac Biotech's return on equity of 0.00% beat Vera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sinovac Biotech	N/A	N/A	N/A
Vera Therapeutics	N/A	-74.86%	-60.18%

In the previous week, Vera Therapeutics had 1 more articles in the media than Sinovac Biotech. MarketBeat recorded 1 mentions for Vera Therapeutics and 0 mentions for Sinovac Biotech. Vera Therapeutics' average media sentiment score of 1.63 beat Sinovac Biotech's score of 0.00 indicating that Vera Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Sinovac Biotech	Neutral
Vera Therapeutics	Very Positive

Summary

Vera Therapeutics beats Sinovac Biotech on 8 of the 12 factors compared between the two stocks.

Get Sinovac Biotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SVA vs. The Competition

Export

Metric	Sinovac Biotech	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$644.66M	$3.37B	$6.46B	$12.34B
Dividend Yield	N/A	2.26%	2.76%	5.28%
P/E Ratio	N/A	18.74	21.21	25.65
Price / Sales	1.78	323.98	554.38	86.31
Price / Cash	3.19	125.17	43.49	56.67
Price / Book	0.06	7.09	10.37	7.14
Net Income	$90.90M	$24.45M	$3.57B	$335.98M
7 Day Performance	N/A	6.38%	6.40%	4.15%
1 Month Performance	N/A	2.43%	3.53%	2.54%
1 Year Performance	N/A	62.98%	34.04%	35.06%

Sinovac Biotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SVA Sinovac Biotech	0.407 of 5 stars	$6.47 flat	N/A	N/A	$644.66M	$361.37M	N/A	2,643	High Trading Volume
GPCR Structure Therapeutics	3.0174 of 5 stars	$36.87 +2.8%	$109.25 +196.3%	+59.6%	$2.54B	N/A	N/A	136
IDYA IDEAYA Biosciences	3.2348 of 5 stars	$29.65 +4.7%	$50.69 +71.0%	+54.6%	$2.49B	$218.71M	N/A	80	Analyst Downgrade
IRON Disc Medicine	2.3566 of 5 stars	$67.03 +4.6%	$105.30 +57.1%	+41.1%	$2.44B	N/A	N/A	30
ARQT Arcutis Biotherapeutics	2.8947 of 5 stars	$20.47 +5.0%	$34.00 +66.1%	+49.2%	$2.44B	$376.07M	N/A	150	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SVA) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sinovac Biotech (SVA) Competitors

SVA vs. GPCR, IDYA, IRON, ARQT, and VERA

How does Sinovac Biotech compare to Structure Therapeutics?

Summary

How does Sinovac Biotech compare to IDEAYA Biosciences?

Summary

How does Sinovac Biotech compare to Disc Medicine?

Summary

How does Sinovac Biotech compare to Arcutis Biotherapeutics?

Summary

How does Sinovac Biotech compare to Vera Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SVA vs. The Competition

Sinovac Biotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sinovac Biotech (SVA) Competitors

SVA vs. GPCR, IDYA, IRON, ARQT, and VERA

How does Sinovac Biotech compare to Structure Therapeutics?

Which has higher earnings & valuation, SVA or GPCR?

Does the media prefer SVA or GPCR?

Do analysts recommend SVA or GPCR?

Which has more risk and volatility, SVA or GPCR?

Do insiders & institutionals believe in SVA or GPCR?

Is SVA or GPCR more profitable?

Summary

How does Sinovac Biotech compare to IDEAYA Biosciences?

Do insiders and institutionals hold more shares of SVA or IDYA?

Is SVA or IDYA more profitable?

Do analysts prefer SVA or IDYA?

Which has more risk and volatility, SVA or IDYA?

Which has higher valuation and earnings, SVA or IDYA?

Does the media refer more to SVA or IDYA?

Summary

How does Sinovac Biotech compare to Disc Medicine?

Do institutionals & insiders believe in IRON or SVA?

Is IRON or SVA more profitable?

Which has better earnings & valuation, IRON or SVA?

Does the media favor IRON or SVA?

Do analysts prefer IRON or SVA?

Which has more volatility and risk, IRON or SVA?

Summary

How does Sinovac Biotech compare to Arcutis Biotherapeutics?

Do analysts rate ARQT or SVA?

Is ARQT or SVA more profitable?

Does the media refer more to ARQT or SVA?

Which has higher earnings and valuation, ARQT or SVA?

Which has more volatility and risk, ARQT or SVA?

Summary

How does Sinovac Biotech compare to Vera Therapeutics?

Which has more risk and volatility, SVA or VERA?

Do analysts rate SVA or VERA?

Which has better earnings and valuation, SVA or VERA?

Do institutionals & insiders believe in SVA or VERA?

Is SVA or VERA more profitable?

Does the media prefer SVA or VERA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SVA vs. The Competition

Sinovac Biotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools